Medications to Expedite Rehabilitation of the Traumatic Brain Injury Patient Austin Trauma & Critical Care Conference May 31, 2018 Kristin Wong, MD, FAAPMR Assistant Professor, Physical Medicine & Rehabilitation
Primary vs. Secondary Brain Injury
Neurotransmitter Storm Beauchamp et al. (2008)
Neuromodulation with Pharmocotherapy Limited level 1 evidence for most medications Majority of studies are limited to small RCT s or case series No medication has received approval from U.S. FDA for the treatment of any posttraumatic neuropsychiatric problem, so all such treatments must be considered off label
Medications reported to improve cognition after TBI Cholinergic Agents Physostigmine (not recommended due to systemic effects) Cytidine-5 -diphosphocholine Cholinesterase inhibitors Donepezil, rivastigmine, galantamine Catecholaminergic agents Psychostimulants (methylphenidate, dextroamphetamine) Amantadine Bromocriptine Levodopa Selegiline Other Agents TCA s?other antidepressants (SSRIs, SNRIs)?Atomoxetine (selective norepinephrine reuptake inhibitor)? Pergolide, pramipexole, ropinirole (dopamine receptor agonists)?guanfacine (selective alpha 2a-adrenergic agonist)?lamotrigine?memantine (N-methyle-D-aspartate receptor antagonist)? = potentially useful agents that have very limited or no support within the clinical TBI literature
Amantadine
Amantadine Dopamine agonist with weak NMDA antagonistic properties Has been shown to accelerate functional recovery and arousal in patients with post-traumatic disorders of consciousness. (Giacino et al, 2012) No reliable data to support the efficacy of pharmacologic intervention in the comatose (Ranchos I) patient Dosing: 100-200mg BID at breakfast and lunch, capsule or syrup. Renally dose. Timing: Start 3 days 5 months post-injury
Methylphenidate Psychostimulant, used for ADHD Dopamine > norepinephrine reuptake inhibitor Dosing: 5-15mg po BID at breakfast and lunch Randomized, double blind crossover design showed that methylphenidate enhances processing speed and increases attention and concentration (Willmott and Ponsford 2009) Greatest medication response was observed in those with more severe head injuries Used in patients that have emerged (Ranchos IV VIII)
Severe TBI (GCS 3-8): Methylphenidate was associated with reductions in ICU and hospital LOS by 23% (P = 0.06 for ICU, P = 0.029 for hospital stay) Moderate TBI (GCS 9-12): 26% reduction only in ICU length of stay (P = 0.05)
Zolpidem GABA potentiator Usually used for insomnia though generally sedating, GABA potentiators may have a paradoxical effect on severe TBI Effective in improving arousal for some severely injured patients (Sara et al, 2009; Whyte and Myers, 2009) 4.8% response rate suggested among those with disorders of consciousness (Whyte et al, 2014)
Address Other Factors Affecting Cognition after TBI Infection Metabolic derangements Neuroendocrine dysfunction Hypoxia Sleep/wake disturbance Sleep hygiene, melatonin, trazodone Overmedication/sedation Seizures
Seizure prophylaxis Given for 7 days after TBI per Evidence Based Guidelines for TBI (Marion 2006) Phenytoin and carbamazepine Associated with treatment-related impairments in cognitive and motor function (Dikmen et al. 1991; Smith et al. 1994) Levetiracetam better tolerated in TBI in the short and long term when compared with phenytoin (Jones et al. 2008; Szaflarski et al. 2010) Valproate relatively benign with respect to effects on cognition and other neurobehavioral functions among persons with TBI (Dikmen et al. 2000) Side effects: hepatic and hematological risks, alopecia, weight gain, polycystic ovarian syndrome Important to discontinue seizure prophylaxis at the end of the first week post-tbi, maintain clinical vigilance for the development of post-traumatic seizures thereafter
Potentially Harmful Typical antipsychotics (haloperidol) exacerbate cognitive impairments and may prolong posttraumatic amnesia (Stanislav 1997; Rao et al. 1985) Benzodiazepines impair memory and other aspects of cognition (Buffett- Jerrott and Stewart 2002) Opioids can cause memory impairments in people w/o TBI, and hence can exacerbate cognitive impairments in those with TBI
General Principles start low, go slow Adequate therapeutic trial Employ therapeutic trials of medications Continuous reassessment Establish a schedule for the systematic reassessment of the clinical condition for which treatment is prescribed Monitor for drug-drug interactions Augmentation Consider augmentation of partial responses to medications Symptom intensification Discontinue or lower the dose of the most recently prescribed medication if there is a worsening of the treated symptoms soon after the medication has been initiated or increased Consider consult other specialists (PM&R, Psychiatry, Neurology)
References Beauchamp K, Mutlak, H, Smith W, Shohami E, Stahel P. (2008) Pharmacology of Traumatic Brain Injury: Where Is the Golden Bullet?. Mol Med 14 (11-12) 731-740. Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, et al. (2012) Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med 366: 819 826. Giacino JT, Katz DI, Whyte J (2013). Neurorehabilitation in disorders of consciousness. Semin Neurol 33: 142 156. Marion DW. Evidenced-based guidelines for traumatic brain injuries. Prog Neurol Surg. 2006;19:171 196. Moein H, Khalili HA, Keramatian K. (2006) Effect of methylphenidate on ICU and hospital length of stay in patients with severe and moderate traumatic brain injury. Clin. Neurol. Neurosurg.108:539 42. Rao N, Jellinek HM, Woolston DC. (1985). Agitation and closed head injury: haloperidol effects on rehabilitation outcome. Archives of Physical Medicine and Rehabilitation, 66, 30 34. Sara M, Pistoia F, Mura E et al. (2009). Intrathecal baclofen in patients with persistent vegetative state: 2 hypotheses. Arch Phys Med Rehabil 90: 1245 1249. Silver, J., Yudofsky, S. and McAllister, T. (2011). Textbook of traumatic brain injury. Washington, DC: American Psychiatric Pub. Stanislav, SW. (1997). Cognitive effects of anti-psychotic agents in persons with traumatic brain injury. Brain Injury, 11, 335 341. Whyte J, Rajan R, Rosenbaum A et al. (2014). Zolpidem and restoration of consciousness. Am J Phys Med Rehabil 93: 101 113. Willmott C, Ponsford J (2009). Efficacy of methylphenidate in the rehabilitation of attention following traumatic brain injury: a randomised crossover double blind placebo controlled inpatient trial. J Neurol Neurosurg Psychiatry 80: 552 557
The End